|Year : 2018 | Volume
| Issue : 16 | Page : 1894-1897
Classical and Emerging Therapies against Chronic Obstructive Pulmonary Disease
Han-Rong Feng, Chao Zhang, Song-Min Ying
Department of Pharmacology & Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, China
|Date of Submission||21-Jun-2018|
|Date of Web Publication||1-Aug-2018|
Dr. Song-Min Ying
Department of Pharmacology & Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058
Source of Support: None, Conflict of Interest: None
Keywords: Biologic Therapies; Chronic Obstructive Pulmonary Disease; Efficacy and Safety
|How to cite this article:|
Feng HR, Zhang C, Ying SM. Classical and Emerging Therapies against Chronic Obstructive Pulmonary Disease. Chin Med J 2018;131:1894-7
|How to cite this URL:|
Feng HR, Zhang C, Ying SM. Classical and Emerging Therapies against Chronic Obstructive Pulmonary Disease. Chin Med J [serial online] 2018 [cited 2018 Sep 20];131:1894-7. Available from: http://www.cmj.org/text.asp?2018/131/16/1894/238133
| Introduction|| |
Chronic obstructive pulmonary disease (COPD) is a worldwide respiratory disease which always co-exists with multiple extrapulmonary comorbidities such as cardiovascular diseases and osteoporosis. The World Health Organization pointed out that till 2030, COPD would be the third leading reason of mortality. In spite of the advanced medical research and health-care efforts, COPD still shows continuously increasing quantity of death. Tobacco smoking, indoor and outdoor air pollution (for example, biomass fuel), virus, and pulmonary dysplasia are the main risk factors for COPD. All these factors eventually destroy lung parenchymal tissue and disturb repair and defense system, which eventually lead to emphysema and small airway fibrosis [Figure 1].
|Figure 1: Diagram for the etiology and pathogenesis of COPD. COPD: Chronic obstructive pulmonary disease.|
Click here to view
The main pathological features of COPD are airway inflammation, oxidative stress, imbalance of protease/antiprotease, and mucus hypersecretion. Inhaled corticosteroids (ICS) and bronchodilators are the most common representatives for COPD therapies. In this editorial, we compare the efficacy and safety of several medications and introduce the emerging biologic therapies for COPD.
| Inhaled Corticosteroids|| |
ICS are a commonly used treatment for 70% of COPD patients, and some of these patients are at low risk of exacerbations. Current guidelines for the management of COPD recommend limiting dose of ICS to patients with more severe disease and increased exacerbation risks. However, the adverse effects of using ICS cannot be ignored. For example, cataract, osteoporosis, and pneumonia have a greater incidence among elderly ICS-administrated patients, which indicates that ICS may have significant side effects related to age. For this reason, the use of ICS in elderly COPD patients should be treated more cautiously.
| Beta2-Adrenoceptor Agonists|| |
Beta2(β2)-adrenoceptor agonists are the most widely used bronchodilators. This kind of agonists has a significant effect on relaxing airway smooth muscle (ASM) as the targeting sites of β2-adrenoceptors (β2-ARs) are located on ASM.
β2-adrenoceptor agonists are classified into two groups according to the acting time: the short-acting β2-adrenoceptor agonists (SABAs) for short-acting time (4–6 h) and the long-acting β2-adrenoceptor agonists (LABAs) for long-acting time (12 h). Respiratory physicians now use LABAs as prophylactic management for bronchoconstriction and SABAs to relieve acute exacerbations.
SABAs are only used as the initial treatment for relieving breathlessness for COPD patients. The most commonly used SABAs are fenoterol, levalbuterol, salbutamol, and terbutaline. They all strongly and specifically react with β2-ARs but not to α-ARs. The advantage of SABAs is that the reacting time is usually within 3–30 min. For example, atomized inhaled salbutamol improves breathing in 5 min and lasts for the next 4–6 h. LABAs are a frontline treatment for COPD patients. Comparing with SABAs, LABAs show longer duration time which is always more than 12 h. Currently, the commonly used LABAs are formoterol and salmeterol. Recently, the ultra-LABAs, which are often efficient for 24 h, have attracted much attention. LABAs and ultra-LABAs both significantly relieve dynamic pulmonary hyperinflation and improve dyspnea and health-related quality of life (HRQoL). Besides, LABAs are more convenient and suitable for COPD patients, while SABAs are mainly used as adjuvant treatment or for temporary need.
| Inhaled Corticosteroids in Combination with Long-Acting Beta2-Adrenoceptor Agonists|| |
ICS are also constantly recommended for treating COPD patients in combination with LABAs. ICS mainly improve airway inflammation, and LABAs dilate bronchial smooth muscle. The combination of these two medications helps COPD patients with a better clinical control. There are several ICS/LABA combinations, for example, budesonide/formoterol and fluticasone/salmeterol are the two frequently used ICS/LABA combinations. Even though when considering an ICS/LABA combination as the therapy for COPD patients, the risk-benefit ratio should still be evaluated strictly.
| Long-Acting Muscarinic Antagonists|| |
Long-acting muscarinic antagonists (LAMAs) is a selective M3-receptor antagonist with obvious efficiency and fewer adverse reactions. Some LAMA/device systems are approved therapies for treating COPD. These medications improve pulmonary function and reduce acute bronchial exacerbations with good safety. Glycopyrronium bromide and aclidinium bromide are two represent LAMAs. Once-daily inhaled glycopyrronium bromide has significant effects on the level of forced expiratory volume in 1 second (FEV1) in patients with moderate-to-severe COPD. Furthermore, a nearly report indicated that once-daily inhaled glycopyrronium bromide provides rapid onset for bronchodilatation and sustains for 24 h.
| Long-Acting Muscarinic Antagonist in Combination with Long-Acting Beta2-Adrenoceptor Agonist|| |
In clinical trials, dual bronchodilation of LAMA/LABA combination was applied over the past few years. Recent preclinical studies found that the combination of these two medications induced better bronchodilation than LAMA alone. Meanwhile, the combination improved many patient-reported outcomes significantly., Furthermore, some studies drew a comparison between LAMA/LABA inhalers and ICS/LABA combination inhalers in moderate-to-severe COPD patients. A study showed that indacaterol–glycopyrronium (a LAMA/LABA combination) was more effectual than salmeterol–fluticasone (a ICS/LABA combination) in preventing COPD exacerbations in patients who had a long history of exacerbations. Another study compared all the currently available LABAs/LAMAs and found that compared to LAMA or LABA/ICS, LAMA/LABA showed greater efficacy and comparable safety profiles, supporting LAMA/LABA combinations as the first-line treatment options for COPD. Moreover, LAMA/LABA provided larger improvement in trough FEV1 versus ICS/LABA. The 2017 guidelines for the Global Initiative for Chronic Obstructive Lung Disease (GOLD) placed LAMA/LABA earlier than ICS in the stepwise escalation of COPD therapy.
These studies demonstrated that LAMA/LABA combinations work synergistically on ASM relaxation. The results also indicated using LAMA/LABA combinations as therapies for COPD. However, it is still a strong medical demand to determine the most suitable LAMA/LABA doses.
| Triple Inhaled Therapy: Long-Acting Muscarinic Antagonist + Long-Acting Beta2-Adrenoceptor Agonist + Inhaled Corticosteroids|| |
Triple inhaled therapy for COPD is constituted with an ICS, a LAMA, and a LABA, which is recommended in the GOLD management tactics for COPD patients who have clinically significant symptoms and of high risk of getting frequent or severe exacerbations in spite of treatment with the combination of ICS/LABA or LAMA/LABA. A study showed that consuming the once-daily single-inhaler triple therapy with fluticasone furoate, umeclidinium, and vilanterol improved a better lung function and HRQoL and a significantly lower rate of moderate or severe COPD exacerbations compared to dual therapy with fluticasone ICS/LABA or LAMA/LABA. In addition, the triple therapy also decreased the rate of hospitalization than LAMA/LABA. Another study proved that the advantages of single-inhaler triple therapy were remarkable compared with ICS/LABA therapy in advanced COPD patients.
| Novel Anti-Eosinophilic Treatments|| |
COPD is conspicuously associated with neutrophilic inflammation, comparing with T-helper 2-mediated eosinophilic airway inflammation which mainly observed in asthma. However, eosinophils might also act as a key role in 10–40% of COPD patients. Interleukin (IL)-5 is a decisive factor in the differentiation and maturation of eosinophils, which is binding to surface receptors of progenitors of eosinophils. Monoclonal IL-5 and IL-5 receptor-α (IL-5Rα) antibodies neutralizing IL-5 or blocking IL-5Rα are recently developed medications for asthma patients, such as mepolizumab and benralizumab, while they were also reported as effective therapies for COPD.
Mepolizumab blocks IL-5 to reduce eosinophil counts in blood and pulmonary tissues. A recent study showed that mepolizumab was related to a lower rate of moderate or severe exacerbations than placebo among COPD patients. Benralizumab is also a humanized monoclonal antibody targeting IL-5RL. The first research of the biologic therapies in COPD reported that benralizumab improved FEV1, without decreasing the rates of exacerbation. These results proved that anti-IL-5 had good effects on lung function in eosinophilic COPD, suggesting that eosinophilic airway inflammation contributed to COPD exacerbations, but the role of eosinophils in COPD exacerbations remains to be clarified.
| Phosphodiesterase-4 Inhibitor|| |
Phosphodiesterase-4 (PDE-4) is a major cAMP-metabolizing enzyme existing both in lung structural and inflammatory cells. The inhibition of PDE-4 increases intracellular cAMP and reduces the activation of inflammatory cells, and PDE-4 inhibitors are a novel medication approved for COPD. Currently, several selective PDE-4 inhibitors are being developed for the treatment of COPD, such as roflumilast, cilomilast, arofylline, AWD-12-281, and SCH-351591. Roflumilast was associated with a prominent (P< 0.01) decrease in neutrophil and eosinophil levels and serum levels of pro-inflammatory cytokines. It reduced pulmonary inflammation by decreasing prolyl endopeptidase activity and acetyl-proline-glycine-proline. In a therapeutic protocol, the influence of using PDE-4 inhibitors to reduce lung fibrosis was almost same to nintedanib and pirfenidone. These results indicated that PDE-4 inhibition could be used for treating fibrotic lung disease. Nevertheless, the fact that PDE-4 inhibitors had side effects on symptoms cannot be ignored. It is common for the patients to get weight loss and gastrointestinal adverse effects. According to the GOLD 2017 guidelines, PDE-4 inhibitors may be better used as add-on therapy in the patients who have persistent symptoms or already accepted optimal COPD management but still in exacerbations.
In conclusion, COPD is a type of obstructive pulmonary disease characterized by long-term breathing problems and poor airflow. This editorial attempts to list some emerging biologic therapies for COPD patients. The main purpose of COPD treatment is to reduce the rate of exacerbations and mortality. In recent decades, much more new therapies have been developed successfully and proved to be effective. However, all the current treatments are reliever medications, which cannot completely prevent the progress of the disease. Thus, the development of new medications to COPD is still the research focus in this field.
| References|| |
Hillas G, Perlikos F, Tsiligianni I, Tzanakis N. Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis 2015;10:95-109. doi: 10.2147/COPD.S54473
Kaplan AG. Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: A proposed algorithm for clinical practice. Int J Chron Obstruct Pulmon Dis 2015;10:2535-48. doi: 10.2147/COPD.S93321.
Rossi AP, Zanardi E, Zamboni M, Rossi A. Optimizing treatment of elderly COPD patients: What role for inhaled corticosteroids? Drugs Aging 2015;32:679-87. doi: 10.1007/s40266-015-0291-8.
Cazzola M, Page CP, Rogliani P, Matera MG. B2-agonist therapy in lung disease. Am J Respir Crit Care Med 2013;187:690-6. doi: 10.1164/rccm.201209-1739PP.
Billington CK, Penn RB, Hall IP. B2 agonists. Handb Exp Pharmacol 2017;237:23-40. doi: 10.1007/164_2016_64.
Latorre M, Novelli F, Vagaggini B, Braido F, Papi A, Sanduzzi A, et al.
Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS. Pulm Pharmacol Ther 2015;30:44-50. doi: 10.1016/j.pupt.2014.10.006.
Melani AS. Long-acting muscarinic antagonists. Expert Rev Clin Pharmacol 2015;8:479-501. doi: 10.1586/17512433.2015.1058154.
Verkindre C, Fukuchi Y, Flémale A, Takeda A, Overend T, Prasad N, et al.
Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients. Respir Med 2010;104:1482-9. doi: 10.1016/j.rmed.2010.04.006.
Tariq SM, Thomas EC. Maintenance therapy in COPD: Time to phase out ICS and switch to the new LAMA/LABA inhalers? Int J Chron Obstruct Pulmon Dis 2017;12:1877-82. doi: 10.2147/COPD.S138006.
Cazzola M, Calzetta L, Page CP, Rogliani P, Facciolo F, Gavaldà A, et al.
Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. Eur J Pharmacol 2014;745:135-43.doi: 10.1016/j.ejphar.2014.10.025.
van der Molen T, Cazzola M. Beyond lung function in COPD management: Effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 2012;21:101-8. doi: 10.4104/pcrj.2011.00102.
Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, et al.
Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N
Engl J Med 2016;374:2222-34. doi: 10.1056/NEJMoa1516385.
Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, et al.
LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: A systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 2017;12:907-22. doi: 10.2147/COPD.S130482.
Horita N, Miyazawa N, Tomaru K, Inoue M, Kaneko T. Long-acting muscarinic antagonist + long-acting beta agonist versus long-acting beta agonist + inhaled corticosteroid for COPD: A systematic review and meta-analysis. Respirology 2015;20:1153-9. doi: 10.1111/resp.12603.
Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2017 Report. Available from: http://www.goldcopd. org
. [Last accessed on 2017 Mar 18].
Calzetta L, Matera MG, Cazzola M. Pharmacological interaction between LABAs and LAMAs in the airways: Optimizing synergy. Eur J Pharmacol 2015;761:168-73. doi: 10.1016/j.ejphar.2015.05.020.
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al.
Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J 2017;49. pii: 1700214. doi: 10.1183/13993003.00214-2017.
Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al.
Once-daily single-inhaler triple versus dual therapy in patients with COPD. N
Engl J Med 2018;378:1671-80. doi: 10.1056/NEJMoa1713901.
Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, et al.
FULFIL trial: Once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017;196:438-46. doi: 10.1164/rccm.201703-0449OC.
Lee JJ, Jacobsen EA, Ochkur SI, McGarry MP, Condjella RM, Doyle AD, et al.
Human versus mouse eosinophils: “that which we call an eosinophil, by any other name would stain as red”. J Allergy Clin Immunol 2012;130:572-84. doi: 10.1016/j.jaci.2012.07.025.
George L, Brightling CE. Eosinophilic airway inflammation: Role in asthma and chronic obstructive pulmonary disease. Ther Adv Chronic Dis 2016;7:34-51. doi: 10.1177/2040622315609251.
Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, et al.
Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N
Engl J Med 2017;377:1613-29. doi: 10.1056/NEJMoa1708208.
Brightling CE, Bleecker ER, Panettieri RA Jr., Bafadhel M, She D, Ward CK, et al.
Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: A randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2014;2:891-901. doi: 10.1016/S2213-2600(14)70187-0.
Luo J, Yang L, Yang J, Yang D, Liu BC, Liu D, et al.
Efficacy and safety of phosphodiesterase 4 inhibitors in patients with asthma: A systematic review and meta-analysis. Respirology 2018;23:467-77. doi: 10.1111/resp.13276.
Garnock-Jones KP. Roflumilast: A review in COPD. Drugs 2015;75:1645-56. doi: 10.1007/s40265-015-0463-1.
Sisson TH, Christensen PJ, Muraki Y, Dils AJ, Chibucos L, Subbotina N, et al.
Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury. Physiol Rep 2018;6:e13753. doi: 10.14814/phy2.13753.
Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2017;9:CD002309. doi: 10.1002/14651858.CD002309.pub5.